LIST OF FIGURES

Figure 1: Schematic view of the most frequent mutated genes and their biological significance in AML cells [9] 12

Figure 2: Schematic description of AML1 and AML1-ETO function 13

Figure 3:RUNX1/ETO assembles multiple epigenetic regulators [13] 14

Figure 4: Oncogenic Fusion Proteins. [16] 16

Figure 5: NPM1 is a multifunctional histone binding protein. 20

Figure 6: Overview of the structure of human leukocyte [66] 47

Figure 7: HLA-G Isoforms and their receptors 47

Figure 8: HLA-G dimer. The Cys42 disulfide-linked homodimer 48

Figure 9: LIR-1 binding to HLA-G dimer. [66] 49

Figure 10: Homomultimeric structures of HLA-G. [76] 49

Figure 11: HLA-G properties towards immune cells 51

Figure 12: Immunoregulatory activities mediated by sHLA-G. Target cells and receptors involved are also indicated.[87] 52

Figure 13: Emergency immune suppression: a possible impact of HLA-G trogocytosis on immune responses. [76] 54

Figure 14: HLA-G expression in tumor lesions 61

Figure 15: Schematic representation of a novel mechanism utilized by human neuroblastoma cells to elude the control of the host's immune system. 63

Figure 16: Comparison between the three studied groups regarding age and gender . 85

Figure 17: Comparison between different studied patients groups regarding FAB classification 87

Figure 18:Comparison between the three studied groups regarding sHLA-G 92

obeikandl.com

Figure 19: Comparison between the two studied patients groups regarding cytogenetic findings 93

Figure 20: ROC curve to determine the sensitivity and specificity of sHLA-G in detection the disease 94

Figure 21: Comparison between sHLA-G and FAB subtypes.....99

obeikandl.com

LIST OF TABLES

Table 1: Common Cytogenetic Abnormalities And Mutations In Acute Myeloid Leukemia 11

Table 2: Risk status based on cytogenetic and molecular abnormalities 29

Table 3: Frequency and prognostic impact of gene mutations in acute myeloid leukemia with normal karyotype 30

Table 4: Prognostic value and impact on treatment decision of selected 38

Table 5: Receptors of HLA-G 50

Table 6: Immunological properties of HLA-G: implications in human diseases. 59

Table 7: Summary of the human diseases associated with HLA-G: roles and clinical applications 65

Table 8: Comparison between the three studied groups regarding age and sex 84

Table 9: Comparison between different studied patients groups regarding FAB classification 86

Table 10: Comparison between the three studied groups regarding blood picture 88

Table 11: Comparison between the three studied groups regarding liver function 89

Table 12: Comparison between the three studied groups regarding kidney function tests 90

Table 13: Comparison between AML studied groups regarding bone marrow blasts 91

Table 14: Comparison between the three studied groups regarding sHLA-G 92

Table 15: Comparison between the two studied patients groups regarding cytogenetic study 93

Table 16: Area Under the Curve 95

Table 17: Coordinates of the Curve 95

Table 18: Relation between sHLA-G and gender 96

Table 19: Correlation between sHLA-G and age and blast percentage. 97

Table 20: Comparison between sHLA-G as regards cytogenetics 97

Table 21: Comparison between sHLA-G and FAB subtypes 98

Table 22: Comparison between sHLA-G and response to therapy 99

obeikandi.com